NVZMF (Novonesis (Novozymes) B) Net Income From Continuing Operations : $487 Mil (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Novonesis (Novozymes) B's net income from continuing operations for the three months ended in Mar. 2025 was $201 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $487 Mil.

Novonesis (Novozymes) B Net Income From Continuing Operations Historical Data

The historical data trend for Novonesis (Novozymes) B's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Net Income From Continuing Operations Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

462.00

477.82

524.05

444.82

320.21

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															237.62	36.20	32.94	253.30	201.08

Novonesis (Novozymes) B Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $487 Mil.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM:Germany NZM:Germany NZM2:Germany NZM2:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.